Bristol-Myers
Squibb Company (NYSE: BMY) today announced that it has completed the
previously announced planned acquisition of Padlock Therapeutics, Inc.
The transaction includes full rights to Padlock’s Protein/Peptidyl
Arginine Deiminase inhibitor discovery program focused on the
development of potentially transformational treatment approaches for
patients with rheumatoid arthritis and other autoimmune diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
and YouTube.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Among other risks, there can be no guarantee that the expected benefits
of the acquisition will be realized. In addition, the compounds
described in this release are subject to all the risks inherent in the
drug development process, and there can be no assurance that the
development of these compounds will be successful. Forward-looking
statements in the press release should be evaluated together with the
many uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion in
Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2015, its Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise.
Bristol-Myers SquibbMedia:Ken Dominski, 609-252-5251ken.dominski@bms.comorInvestors:Ranya Dajani, 609-252-5330ranya.dajani@bms.comorBill Szablewski, 609-252-5894william.szablewski@bms.com